ParkinsonCanadaV1, PascalFrancis, Curation, bibRecord, 000C11

Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease

Identifieur interne : 000C11 ( PascalFrancis/Curation ); précédent : 000C10; suivant : 000C12

Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease

Auteurs : Claudine Habak [Canada] ; Anne Noreau [Canada] ; Atsuko Nagano-Saito [Canada] ; Beatriz Mejia-Constain [Canada] ; Clotilde Degroot [Canada] ; Antonio P. Strafella [Canada] ; Sylvain Chouinard [Canada] ; Anne-Louise Lafontaine [Canada] ; Guy A. Rouleau [Canada] ; Oury Monchi [Canada]

Source :

Brain [ 0006-8950 ] ; 2014.

RBID : Pascal:14-0260817

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Dopamine, Génotype, Polymorphisme, Fonction exécutive, Imagerie RMN.

English descriptors

KwdEn :
- Dopamine, Executive function, Genotype, Nervous system diseases, Nuclear magnetic resonance imaging, Parkinson disease, Polymorphism.

Abstract

Parkinson's disease is a neurodegenerative condition that affects motor function along with a wide range of cognitive domains, including executive function. The hallmark of the pathology is its significant loss of nigrostriatal dopamine, which is necessary for the cortico-striatal interactions that underlie executive control. Striatal dopamine reuptake is mediated by the SLC6A3 gene (formerly named DAT1) and its polymorphisms, which have been largely overlooked in Parkinson's disease. Thirty patients (ages 53-68 years; 19 males, 11 females) at early stages of Parkinson's disease, were genotyped according to a 9-repeat (9R) or 10-repeat (10R) allele on the SLC6A3/DAT1 gene. They underwent neuropsychological assessment and functional magnetic resonance imaging while performing a set-shifting task (a computerized Wisconsin Card Sorting Task) that relies on fronto-striatal interactions. Patients homozygous on the 10R allele performed significantly better on working memory tasks than 9R-carrier patients. Most importantly, patients carrying a 9R allele exhibited less activation than their 10R homozygous counterparts in the prefrontal cortex, premotor cortex and caudate nucleus, when planning and executing a set-shift. This pattern was exacerbated for conditions that usually recruit the striatum compared to those that do not. This is the first study indicating that the SLC6A3/ DAT1 genotype has a significant effect on fronto-striatal activation and performance in Parkinson's disease. This effect is stronger for conditions that engage the striatum. Longitudinal studies are warranted to assess this polymorphism's effect on the clinical evolution of patients with Parkinson's disease, especially with cognitive decline.

A01	`01`	`1`		`@0 0006-8950`
A03		`1`		`@0 Brain`
A05				`@2 137`
A06				`@3 p. 11`
A08	`01`	`1`	`ENG`	`@1 Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease`
A11	`01`	`1`		`@1 HABAK (Claudine)`
A11	`02`	`1`		`@1 NOREAU (Anne)`
A11	`03`	`1`		`@1 NAGANO-SAITO (Atsuko)`
A11	`04`	`1`		`@1 MEJIA-CONSTAIN (Beatriz)`
A11	`05`	`1`		`@1 DEGROOT (Clotilde)`
A11	`06`	`1`		`@1 STRAFELLA (Antonio P.)`
A11	`07`	`1`		`@1 CHOUINARD (Sylvain)`
A11	`08`	`1`		`@1 LAFONTAINE (Anne-Louise)`
A11	`09`	`1`		`@1 ROULEAU (Guy A.)`
A11	`10`	`1`		`@1 MONCHI (Oury)`
A14	`01`			`@1 Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal @2 Montréal, Quebec, H3W 1W5 @3 CAN @Z 1 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 10 aut.`
A14	`02`			`@1 Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM) @2 Montreal, Québec @3 CAN @Z 2 aut. @Z 7 aut. @Z 9 aut.`
A14	`03`			`@1 Department of Neurology and Neurosurgery, McGill University @2 Montréal, QC H3A 2B4 @3 CAN @Z 2 aut. @Z 8 aut. @Z 9 aut.`
A14	`04`			`@1 Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto @2 Ontario @3 CAN @Z 6 aut.`
A14	`05`			`@1 Département de Radiologie, Université de Montréal @2 Montréal, Québec @3 CAN @Z 10 aut.`
A20				`@1 3025-3035`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 998 @5 354000502668820180`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 1 p.1/4`
A47	`01`	`1`		`@0 14-0260817`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Brain`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Parkinson's disease is a neurodegenerative condition that affects motor function along with a wide range of cognitive domains, including executive function. The hallmark of the pathology is its significant loss of nigrostriatal dopamine, which is necessary for the cortico-striatal interactions that underlie executive control. Striatal dopamine reuptake is mediated by the SLC6A3 gene (formerly named DAT1) and its polymorphisms, which have been largely overlooked in Parkinson's disease. Thirty patients (ages 53-68 years; 19 males, 11 females) at early stages of Parkinson's disease, were genotyped according to a 9-repeat (9R) or 10-repeat (10R) allele on the SLC6A3/DAT1 gene. They underwent neuropsychological assessment and functional magnetic resonance imaging while performing a set-shifting task (a computerized Wisconsin Card Sorting Task) that relies on fronto-striatal interactions. Patients homozygous on the 10R allele performed significantly better on working memory tasks than 9R-carrier patients. Most importantly, patients carrying a 9R allele exhibited less activation than their 10R homozygous counterparts in the prefrontal cortex, premotor cortex and caudate nucleus, when planning and executing a set-shift. This pattern was exacerbated for conditions that usually recruit the striatum compared to those that do not. This is the first study indicating that the SLC6A3/ DAT1 genotype has a significant effect on fronto-striatal activation and performance in Parkinson's disease. This effect is stronger for conditions that engage the striatum. Longitudinal studies are warranted to assess this polymorphism's effect on the clinical evolution of patients with Parkinson's disease, especially with cognitive decline.
C02	`01`	`X`		`@0 002B17G`
C02	`02`	`X`		`@0 002B17A01`
C02	`03`	`X`		`@0 002B17A03`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Génotype @5 10`
C03	`04`	`X`	`ENG`	`@0 Genotype @5 10`
C03	`04`	`X`	`SPA`	`@0 Genotipo @5 10`
C03	`05`	`X`	`FRE`	`@0 Polymorphisme @5 11`
C03	`05`	`X`	`ENG`	`@0 Polymorphism @5 11`
C03	`05`	`X`	`SPA`	`@0 Polimorfismo @5 11`
C03	`06`	`X`	`FRE`	`@0 Fonction exécutive @5 12`
C03	`06`	`X`	`ENG`	`@0 Executive function @5 12`
C03	`06`	`X`	`SPA`	`@0 Función ejecutiva @5 12`
C03	`07`	`X`	`FRE`	`@0 Imagerie RMN @5 13`
C03	`07`	`X`	`ENG`	`@0 Nuclear magnetic resonance imaging @5 13`
C03	`07`	`X`	`SPA`	`@0 Imaginería RMN @5 13`
C07	`01`	`X`	`FRE`	`@0 Catécholamine @5 37`
C07	`01`	`X`	`ENG`	`@0 Catecholamine @5 37`
C07	`01`	`X`	`SPA`	`@0 Catecolamina @5 37`
C07	`02`	`X`	`FRE`	`@0 Neurotransmetteur @5 38`
C07	`02`	`X`	`ENG`	`@0 Neurotransmitter @5 38`
C07	`02`	`X`	`SPA`	`@0 Neurotransmisor @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 42`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 42`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 42`
C07	`07`	`X`	`FRE`	`@0 Imagerie médicale @5 44`
C07	`07`	`X`	`ENG`	`@0 Medical imagery @5 44`
C07	`07`	`X`	`SPA`	`@0 Imaginería médica @5 44`
N21				`@1 321`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000007

Links to Exploration step

Pascal:14-0260817

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease</title>
<author><name sortKey="Habak, Claudine" sort="Habak, Claudine" uniqKey="Habak C" first="Claudine" last="Habak">Claudine Habak</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Noreau, Anne" sort="Noreau, Anne" uniqKey="Noreau A" first="Anne" last="Noreau">Anne Noreau</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)</s1>
<s2>Montreal, Québec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology and Neurosurgery, McGill University</s1>
<s2>Montréal, QC H3A 2B4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Nagano Saito, Atsuko" sort="Nagano Saito, Atsuko" uniqKey="Nagano Saito A" first="Atsuko" last="Nagano-Saito">Atsuko Nagano-Saito</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Mejia Constain, Beatriz" sort="Mejia Constain, Beatriz" uniqKey="Mejia Constain B" first="Beatriz" last="Mejia-Constain">Beatriz Mejia-Constain</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Degroot, Clotilde" sort="Degroot, Clotilde" uniqKey="Degroot C" first="Clotilde" last="Degroot">Clotilde Degroot</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P." last="Strafella">Antonio P. Strafella</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto</s1>
<s2>Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)</s1>
<s2>Montreal, Québec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Lafontaine, Anne Louise" sort="Lafontaine, Anne Louise" uniqKey="Lafontaine A" first="Anne-Louise" last="Lafontaine">Anne-Louise Lafontaine</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology and Neurosurgery, McGill University</s1>
<s2>Montréal, QC H3A 2B4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Rouleau, Guy A" sort="Rouleau, Guy A" uniqKey="Rouleau G" first="Guy A." last="Rouleau">Guy A. Rouleau</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)</s1>
<s2>Montreal, Québec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology and Neurosurgery, McGill University</s1>
<s2>Montréal, QC H3A 2B4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Département de Radiologie, Université de Montréal</s1>
<s2>Montréal, Québec</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0260817</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0260817 INIST</idno>
<idno type="RBID">Pascal:14-0260817</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000007</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000C11</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease</title>
<author><name sortKey="Habak, Claudine" sort="Habak, Claudine" uniqKey="Habak C" first="Claudine" last="Habak">Claudine Habak</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Noreau, Anne" sort="Noreau, Anne" uniqKey="Noreau A" first="Anne" last="Noreau">Anne Noreau</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)</s1>
<s2>Montreal, Québec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology and Neurosurgery, McGill University</s1>
<s2>Montréal, QC H3A 2B4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Nagano Saito, Atsuko" sort="Nagano Saito, Atsuko" uniqKey="Nagano Saito A" first="Atsuko" last="Nagano-Saito">Atsuko Nagano-Saito</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Mejia Constain, Beatriz" sort="Mejia Constain, Beatriz" uniqKey="Mejia Constain B" first="Beatriz" last="Mejia-Constain">Beatriz Mejia-Constain</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Degroot, Clotilde" sort="Degroot, Clotilde" uniqKey="Degroot C" first="Clotilde" last="Degroot">Clotilde Degroot</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P." last="Strafella">Antonio P. Strafella</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto</s1>
<s2>Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Chouinard, Sylvain" sort="Chouinard, Sylvain" uniqKey="Chouinard S" first="Sylvain" last="Chouinard">Sylvain Chouinard</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)</s1>
<s2>Montreal, Québec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Lafontaine, Anne Louise" sort="Lafontaine, Anne Louise" uniqKey="Lafontaine A" first="Anne-Louise" last="Lafontaine">Anne-Louise Lafontaine</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology and Neurosurgery, McGill University</s1>
<s2>Montréal, QC H3A 2B4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Rouleau, Guy A" sort="Rouleau, Guy A" uniqKey="Rouleau G" first="Guy A." last="Rouleau">Guy A. Rouleau</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)</s1>
<s2>Montreal, Québec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology and Neurosurgery, McGill University</s1>
<s2>Montréal, QC H3A 2B4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Monchi, Oury" sort="Monchi, Oury" uniqKey="Monchi O" first="Oury" last="Monchi">Oury Monchi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Département de Radiologie, Université de Montréal</s1>
<s2>Montréal, Québec</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Brain</title>
<title level="j" type="abbreviated">Brain</title>
<idno type="ISSN">0006-8950</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Brain</title>
<title level="j" type="abbreviated">Brain</title>
<idno type="ISSN">0006-8950</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine</term>
<term>Executive function</term>
<term>Genotype</term>
<term>Nervous system diseases</term>
<term>Nuclear magnetic resonance imaging</term>
<term>Parkinson disease</term>
<term>Polymorphism</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Dopamine</term>
<term>Génotype</term>
<term>Polymorphisme</term>
<term>Fonction exécutive</term>
<term>Imagerie RMN</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease is a neurodegenerative condition that affects motor function along with a wide range of cognitive domains, including executive function. The hallmark of the pathology is its significant loss of nigrostriatal dopamine, which is necessary for the cortico-striatal interactions that underlie executive control. Striatal dopamine reuptake is mediated by the SLC6A3 gene (formerly named DAT1) and its polymorphisms, which have been largely overlooked in Parkinson's disease. Thirty patients (ages 53-68 years; 19 males, 11 females) at early stages of Parkinson's disease, were genotyped according to a 9-repeat (9R) or 10-repeat (10R) allele on the SLC6A3/DAT1 gene. They underwent neuropsychological assessment and functional magnetic resonance imaging while performing a set-shifting task (a computerized Wisconsin Card Sorting Task) that relies on fronto-striatal interactions. Patients homozygous on the 10R allele performed significantly better on working memory tasks than 9R-carrier patients. Most importantly, patients carrying a 9R allele exhibited less activation than their 10R homozygous counterparts in the prefrontal cortex, premotor cortex and caudate nucleus, when planning and executing a set-shift. This pattern was exacerbated for conditions that usually recruit the striatum compared to those that do not. This is the first study indicating that the SLC6A3/ DAT1 genotype has a significant effect on fronto-striatal activation and performance in Parkinson's disease. This effect is stronger for conditions that engage the striatum. Longitudinal studies are warranted to assess this polymorphism's effect on the clinical evolution of patients with Parkinson's disease, especially with cognitive decline.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0006-8950</s0>
</fA01>
<fA03 i2="1"><s0>Brain</s0>
</fA03>
<fA05><s2>137</s2>
</fA05>
<fA06><s3>p. 11</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HABAK (Claudine)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>NOREAU (Anne)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>NAGANO-SAITO (Atsuko)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MEJIA-CONSTAIN (Beatriz)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>DEGROOT (Clotilde)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>STRAFELLA (Antonio P.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>CHOUINARD (Sylvain)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>LAFONTAINE (Anne-Louise)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>ROULEAU (Guy A.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>MONCHI (Oury)</s1>
</fA11>
<fA14 i1="01"><s1>Research Centre, Institut universitaire de Gériatrie de Montréal, University of Montréal</s1>
<s2>Montréal, Quebec, H3W 1W5</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)</s1>
<s2>Montreal, Québec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology and Neurosurgery, McGill University</s1>
<s2>Montréal, QC H3A 2B4</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Movement Disorder Unit and E.J. Safra Parkinson Disease Program, Toronto Western Hospital, UHN, University of Toronto</s1>
<s2>Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Département de Radiologie, Université de Montréal</s1>
<s2>Montréal, Québec</s2>
<s3>CAN</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>3025-3035</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>998</s2>
<s5>354000502668820180</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>1 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0260817</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Brain</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Parkinson's disease is a neurodegenerative condition that affects motor function along with a wide range of cognitive domains, including executive function. The hallmark of the pathology is its significant loss of nigrostriatal dopamine, which is necessary for the cortico-striatal interactions that underlie executive control. Striatal dopamine reuptake is mediated by the SLC6A3 gene (formerly named DAT1) and its polymorphisms, which have been largely overlooked in Parkinson's disease. Thirty patients (ages 53-68 years; 19 males, 11 females) at early stages of Parkinson's disease, were genotyped according to a 9-repeat (9R) or 10-repeat (10R) allele on the SLC6A3/DAT1 gene. They underwent neuropsychological assessment and functional magnetic resonance imaging while performing a set-shifting task (a computerized Wisconsin Card Sorting Task) that relies on fronto-striatal interactions. Patients homozygous on the 10R allele performed significantly better on working memory tasks than 9R-carrier patients. Most importantly, patients carrying a 9R allele exhibited less activation than their 10R homozygous counterparts in the prefrontal cortex, premotor cortex and caudate nucleus, when planning and executing a set-shift. This pattern was exacerbated for conditions that usually recruit the striatum compared to those that do not. This is the first study indicating that the SLC6A3/ DAT1 genotype has a significant effect on fronto-striatal activation and performance in Parkinson's disease. This effect is stronger for conditions that engage the striatum. Longitudinal studies are warranted to assess this polymorphism's effect on the clinical evolution of patients with Parkinson's disease, especially with cognitive decline.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17A01</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Génotype</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Genotype</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Genotipo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Polymorphisme</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Polymorphism</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Polimorfismo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Fonction exécutive</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Executive function</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Función ejecutiva</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Imagerie RMN</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Nuclear magnetic resonance imaging</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Imaginería RMN</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Imagerie médicale</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Medical imagery</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Imaginería médica</s0>
<s5>44</s5>
</fC07>
<fN21><s1>321</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C11 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000C11 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0260817
   |texte=   Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease

Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri